Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00187174 · ClinicalTrials.gov registry record · Phase 1
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
A Phase 1 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT00187174 is a Phase 1 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 41 participants.
The verdict
NCT00187174, a Phase 1 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
Patients with recurrent or refractory solid tumors or brain tumors that are unresponsive to conventional therapy, or with no known effective therapy, will be treated. Experiments in the laboratory have shown the experimental drug RAD001C (RAD001, Everolimus) can prevent cells from multiplying. RAD001 is now being tested in diseases such as cancer, in which excessive cell multiplication needs to be stopped. The drug has been tested in adult cancer patients and has been well tolerated by subjects in these studies. It is experimental and, therefore, available in clinical trials.
Interventions
- DRUG Everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2004-10 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00187174
The ClinicalTrials.gov registry entry for NCT00187174 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Everolimus is the first listed.
NCT00187174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00187174 about?
NCT00187174 is a clinical study titled "Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors". Patients with recurrent or refractory solid tumors or brain tumors that are unresponsive to conventional therapy, or with no known effective therapy, will be treated. Experiments in the laboratory have shown the experimental drug RAD001C (RAD001, Everolimus) can prevent cells from multiplying. RAD00...
What is the current status of trial NCT00187174?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2004-10. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00187174?
The interventions under investigation include: Everolimus (DRUG).
Who is sponsoring clinical trial NCT00187174?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.